Table 1

Main characteristics of patients according to treatment group before and after matching or weighting
Median [Q1-Q3] Allo-SCT Controls p-value
N (%)
MM
Original set n=23 n=142
Age 48 [40.5-51] 51.5 [47-55] 0.005
Beta2 ≥ 3.5 4 (17 %) 52 (37 %) 0.12
Months to relapse 16 [11–32.5] 26.5 [17-38] 0.014
Matched set n=21 n=21
Age 49 [41-51] 46 [42-50] 0.24
Beta2 ≥ 3.5 4 (19 %) 4 (19 %) 0.71
Months to relapse 17 [13-33] 24 [17-32] 0.22
Weighted set n=268 n=165
Age 56 [51-58] 51 [46-54] 0.15
Beta2 ≥ 3.5 4 (19%) 4 (19%) 0.28
Months to relapse 58 [26–70] 25 [17-36] 0.08
FL
Original set n=28 n=115
Age 38 [33-42] 46 [40-52] 0.0001
No previous regimens 4 [3,4] 3 [2-4] 0.005
Months to relapse 6.7 [5.6-9.2] 4.6 [3.7-6.1] 0.0001
Matched set n=19 n=19
Age 38 [33-42] 38 [33-45] 0.35
No previous regimens 3 [3,4] 3 [3,4] 0.90
Months to relapse 6.3 [4.7-8.9] 7.8 [4.0-10.7] 0.82
Weighted set n=78 n=117
Age 39 [35-46] 44 [34-50] 0.42
No previous regimens 3 [3,4] 3 [2-4] 0.16
Months to relapse 5.9 [4.7-7.4] 5.3 [3.8-9.3] 0.03
Hodgkin disease
Original set n=23 n=19
Age 23 [19-29] 29 [24-35] 0.05
No previous regimens 4 [3,4] 4 [4,5] 0.05
Months to relapse 1.2 [0–9.2] 2.4 [0–7.2] 0.94
Matched set n=15 n=15
Age 24 [21-31] 25 [23-30] 0.98
No previous regimens 3 [3,4] 4 [4,5] 0.21
Months to relapse 1.9 [0.3-9.9] 1.8 [0–5.4] 0.49
Weighted set n=41 n=40
Age 26 [20-49] 25 [20-32] 0.71
No previous regimens 3 [3,4] 4 [4] 0.17
Months to relapse 0.1 [0–0.7] 0.1 [0–0.5] 0.35

Resche-Rigon et al.

Resche-Rigon et al. BMC Blood Disorders 2012 12:10   doi:10.1186/1471-2326-12-10

Open Data